The Latest Cardiac and Vascular News
– REBLOZYL® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions; FDA review of the sBLA for the lower-risk myelodysplastic syndromes indication is ongoing – – Multiple clinical presentations reviewed at the […]
EDEN PRAIRIE, Minn., Feb. 26, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS) today announced FDA 510(k) clearance in the U.S. of its next generation Aquadex SmartFlow console for use in adult and pediatric patients who weigh 20kg or more. The console is a simple, gentle, and smart solution for treatment of patients suffering from hypervolemia […]
Resuscitation programs and education for fire service leaders are central elements to improve survival rates DALLAS, Feb. 27, 2020 /PRNewswire/ — The American Heart Association states more than 350,000 out-of-hospital cardiac arrests occur in the United States annually. About 90% of people who experience an out-of-hospital cardiac arrest die. A time-critical, life-threatening condition, out-of-hospital cardiac arrest […]
ZURICH, Feb. 27, 2020 /PRNewswire/ — Neurimmune AG, the discoverer of aducanumab and cinpanemab, announced today enrollment of the first patient in a Phase 1 clinical trial to evaluate NI006 in transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy). NI006 is a human antibody directed against transthyretin amyloid (TTR amyloid) consisting of misfolded and aggregated […]
– Appoints Kevin R. Lind as President and Chief Executive Officer of Arena Neuroscience, Inc. – Appoints Laurie D. Stelzer as Executive Vice President and Chief Financial Officer of Arena – Expects to deliver up to eight major data readouts between 2020-21 and multiple INDs – Progressing first- or best-in-class […]
NEW YORK and MELBOURNE, Australia, Feb. 26, 2020 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported financial, corporate and operational highlights for the half year ended December 31, 2019. Mesoblast Chief Executive Dr Silviu Itescu stated: “We are very pleased with the substantial progress made by the Company as […]
Birla co-published paper with Stuart K. Williams, a renowned industry figure, to highlight 3D bioprinting’s impact on cardiac failure treatment CHICAGO, Feb. 27, 2020 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced its Chief Science Officer, Dr. […]
SUNNYVALE, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2019. Recent Highlights Revenue of $18.6 million for the […]
– NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins – – First Non-Statin, LDL-Cholesterol Lowering Combination Medicine Ever Approved – – Esperion’s Second Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. Following NEXLETOL™ (bempedoic acid) Tablet Approval on February 21, […]
Asprihale® is intended for emergency treatment to reduce the risk of vascular mortality in patients with suspected acute myocardial infarction (MI). LOS ANGELES–(BUSINESS WIRE)–Otitopic today announces that it is advancing towards its pivotal PK/PD study following discussions with the FDA. The randomized pivotal study, which is expected to initiate in the […]
